# Mahzi Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mahzi-therapeutics

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.mahzi.com
- Total disclosed funding: $51M
- Latest round: Series A (Oct 25, 2022)
- Investors on record: 1

## About

Founded in 2020 and based in California, US, Mahzi Therapeutics Inc. is a healthcare and biotechnology research company that focuses on treating rare genetic neurodevelopmental disorders. In October 2022, Mahzi Therapeutics Inc. raised USD 4 million in Series A funding from HBM Partners. As of 2023, the company is led by its CEO, Yael Weiss.

The company has expertise in identifying and developing tailored therapeutic approaches for each distinct neurodevelopmental disorder. The firm’s pipeline includes disease identification and understanding, where the initial phase involves comprehensive research to identify, comprehend, and define the specific nuances of each targeted disorder, such as WOREE/SCAR12 (WWOX Deficiency), Pitt Hopkins (TCF4 Deficiency), and CHD2 Deficiency.

The firm then undergoes pre-clinical development and conducts pre-clinical studies, employing scientific methodologies to assess the feasibility and efficacy of potential therapeutic interventions. Mahzi then focuses on meeting regulatory requirements and ensuring the safety and efficacy of its prospective treatments before advancing to human trials. Finally, the company initiates human trials to evaluate the safety and efficacy of the developed therapies.

## Funding rounds

- Series A, Oct 25, 2022, $4M — HBM Partners
- Series A, Oct 7, 2021, $47M — HBM Partners

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A